Frontier Biotechnologies Balance Sheet Health
Financial Health criteria checks 5/6
Frontier Biotechnologies has a total shareholder equity of CN¥1.1B and total debt of CN¥448.6M, which brings its debt-to-equity ratio to 39%. Its total assets and total liabilities are CN¥2.0B and CN¥856.4M respectively.
Key information
39.0%
Debt to equity ratio
CN¥448.63m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥662.47m |
| Equity | CN¥1.15b |
| Total liabilities | CN¥856.41m |
| Total assets | CN¥2.01b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688221's short term assets (CN¥1.0B) exceed its short term liabilities (CN¥476.2M).
Long Term Liabilities: 688221's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥380.2M).
Debt to Equity History and Analysis
Debt Level: 688221 has more cash than its total debt.
Reducing Debt: 688221's debt to equity ratio has increased from 4.4% to 39% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688221 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 688221 has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 7% each year.